46
Participants
Start Date
June 18, 2020
Primary Completion Date
November 16, 2021
Study Completion Date
November 16, 2021
PF-04965842 200 mg
PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
PF-04965842 100 mg
PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
Placebo
Placebo administered as two tablets to be taken orally once daily for 12 weeks
Icahn School of Medicine at Mount Sinai, New York
ForCare Clinical Research, Tampa
Olympian Clinical Research, Largo
The Indiana Clinical Trials Center, PC - Dermatology Research, Plainfield
Wayne Health - Wayne State Dermatology, Dearborn
Menter Dermatology Research Institute, Dallas
Keck School of Medicine of USC - IDS Pharmacy, Los Angeles
USC/Norris Comprehensive Cancer Center, Los Angeles
California Dermatology & Clinical Research Institute, Encinitas
Beacon Dermatology, Calgary
Innovaderm Research, Inc., Montreal
Lead Sponsor
Pfizer
INDUSTRY